
Global FIC Single-target Drugs Market Growth 2024-2030
Description
Global FIC Single-target Drugs Market Growth 2024-2030
FIC (First in Class) refers to a drug that is first-in-class and is created by gradually synthesizing candidate compounds from scratch by finding new drug targets, mechanisms of action, and molecular structures. Through repeated trials and screening, the drug is ultimately found to meet the requirements of both therapeutic effects and human safety (tolerance, pharmacokinetics).
The global FIC Single-target Drugs market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “FIC Single-target Drugs Industry Forecast” looks at past sales and reviews total world FIC Single-target Drugs sales in 2023, providing a comprehensive analysis by region and market sector of projected FIC Single-target Drugs sales for 2024 through 2030. With FIC Single-target Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world FIC Single-target Drugs industry.
This Insight Report provides a comprehensive analysis of the global FIC Single-target Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on FIC Single-target Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global FIC Single-target Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for FIC Single-target Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global FIC Single-target Drugs.
United States market for FIC Single-target Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for FIC Single-target Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for FIC Single-target Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key FIC Single-target Drugs players cover Pfizer, Johnson & Johnson, Merck, Roche, Novartis, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of FIC Single-target Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
RORγ Covalent Inhibitors
Citron Inhibitors
ALK2 Inhibitors
GCN2 Agonists
Others
Segmentation by Application:
Hospital
Clinic
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Pfizer
Johnson & Johnson
Merck
Roche
Novartis
BMS
ImmunoGen
Sanofi
Immunocore
Genentech
Eli Lilly
Agios
Boehringer Ingelheim
Gilead
Mallinckrodt
Phathom
Dermavant Sciences
Polarean lmaging
Marinus
Key Questions Addressed in this Report
What is the 10-year outlook for the global FIC Single-target Drugs market?
What factors are driving FIC Single-target Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do FIC Single-target Drugs market opportunities vary by end market size?
How does FIC Single-target Drugs break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
136 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats
- 2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global FIC Single-target Drugs Annual Sales 2019-2030
- 2.1.2 World Current & Future Analysis for FIC Single-target Drugs by Geographic Region, 2019, 2023 & 2030
- 2.1.3 World Current & Future Analysis for FIC Single-target Drugs by Country/Region, 2019, 2023 & 2030
- 2.2 FIC Single-target Drugs Segment by Type
- 2.2.1 RORγ Covalent Inhibitors
- 2.2.2 Citron Inhibitors
- 2.2.3 ALK2 Inhibitors
- 2.2.4 GCN2 Agonists
- 2.2.5 Others
- 2.3 FIC Single-target Drugs Sales by Type
- 2.3.1 Global FIC Single-target Drugs Sales Market Share by Type (2019-2024)
- 2.3.2 Global FIC Single-target Drugs Revenue and Market Share by Type (2019-2024)
- 2.3.3 Global FIC Single-target Drugs Sale Price by Type (2019-2024)
- 2.4 FIC Single-target Drugs Segment by Application
- 2.4.1 Hospital
- 2.4.2 Clinic
- 2.4.3 Other
- 2.5 FIC Single-target Drugs Sales by Application
- 2.5.1 Global FIC Single-target Drugs Sale Market Share by Application (2019-2024)
- 2.5.2 Global FIC Single-target Drugs Revenue and Market Share by Application (2019-2024)
- 2.5.3 Global FIC Single-target Drugs Sale Price by Application (2019-2024)
- 3 Global by Company
- 3.1 Global FIC Single-target Drugs Breakdown Data by Company
- 3.1.1 Global FIC Single-target Drugs Annual Sales by Company (2019-2024)
- 3.1.2 Global FIC Single-target Drugs Sales Market Share by Company (2019-2024)
- 3.2 Global FIC Single-target Drugs Annual Revenue by Company (2019-2024)
- 3.2.1 Global FIC Single-target Drugs Revenue by Company (2019-2024)
- 3.2.2 Global FIC Single-target Drugs Revenue Market Share by Company (2019-2024)
- 3.3 Global FIC Single-target Drugs Sale Price by Company
- 3.4 Key Manufacturers FIC Single-target Drugs Producing Area Distribution, Sales Area, Product Type
- 3.4.1 Key Manufacturers FIC Single-target Drugs Product Location Distribution
- 3.4.2 Players FIC Single-target Drugs Products Offered
- 3.5 Market Concentration Rate Analysis
- 3.5.1 Competition Landscape Analysis
- 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
- 3.6 New Products and Potential Entrants
- 3.7 Market M&A Activity & Strategy
- 4 World Historic Review for FIC Single-target Drugs by Geographic Region
- 4.1 World Historic FIC Single-target Drugs Market Size by Geographic Region (2019-2024)
- 4.1.1 Global FIC Single-target Drugs Annual Sales by Geographic Region (2019-2024)
- 4.1.2 Global FIC Single-target Drugs Annual Revenue by Geographic Region (2019-2024)
- 4.2 World Historic FIC Single-target Drugs Market Size by Country/Region (2019-2024)
- 4.2.1 Global FIC Single-target Drugs Annual Sales by Country/Region (2019-2024)
- 4.2.2 Global FIC Single-target Drugs Annual Revenue by Country/Region (2019-2024)
- 4.3 Americas FIC Single-target Drugs Sales Growth
- 4.4 APAC FIC Single-target Drugs Sales Growth
- 4.5 Europe FIC Single-target Drugs Sales Growth
- 4.6 Middle East & Africa FIC Single-target Drugs Sales Growth
- 5 Americas
- 5.1 Americas FIC Single-target Drugs Sales by Country
- 5.1.1 Americas FIC Single-target Drugs Sales by Country (2019-2024)
- 5.1.2 Americas FIC Single-target Drugs Revenue by Country (2019-2024)
- 5.2 Americas FIC Single-target Drugs Sales by Type (2019-2024)
- 5.3 Americas FIC Single-target Drugs Sales by Application (2019-2024)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil
- 6 APAC
- 6.1 APAC FIC Single-target Drugs Sales by Region
- 6.1.1 APAC FIC Single-target Drugs Sales by Region (2019-2024)
- 6.1.2 APAC FIC Single-target Drugs Revenue by Region (2019-2024)
- 6.2 APAC FIC Single-target Drugs Sales by Type (2019-2024)
- 6.3 APAC FIC Single-target Drugs Sales by Application (2019-2024)
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan
- 7 Europe
- 7.1 Europe FIC Single-target Drugs by Country
- 7.1.1 Europe FIC Single-target Drugs Sales by Country (2019-2024)
- 7.1.2 Europe FIC Single-target Drugs Revenue by Country (2019-2024)
- 7.2 Europe FIC Single-target Drugs Sales by Type (2019-2024)
- 7.3 Europe FIC Single-target Drugs Sales by Application (2019-2024)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
- 8 Middle East & Africa
- 8.1 Middle East & Africa FIC Single-target Drugs by Country
- 8.1.1 Middle East & Africa FIC Single-target Drugs Sales by Country (2019-2024)
- 8.1.2 Middle East & Africa FIC Single-target Drugs Revenue by Country (2019-2024)
- 8.2 Middle East & Africa FIC Single-target Drugs Sales by Type (2019-2024)
- 8.3 Middle East & Africa FIC Single-target Drugs Sales by Application (2019-2024)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
- 9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends
- 10 Manufacturing Cost Structure Analysis
- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of FIC Single-target Drugs
- 10.3 Manufacturing Process Analysis of FIC Single-target Drugs
- 10.4 Industry Chain Structure of FIC Single-target Drugs
- 11 Marketing, Distributors and Customer
- 11.1 Sales Channel
- 11.1.1 Direct Channels
- 11.1.2 Indirect Channels
- 11.2 FIC Single-target Drugs Distributors
- 11.3 FIC Single-target Drugs Customer
- 12 World Forecast Review for FIC Single-target Drugs by Geographic Region
- 12.1 Global FIC Single-target Drugs Market Size Forecast by Region
- 12.1.1 Global FIC Single-target Drugs Forecast by Region (2025-2030)
- 12.1.2 Global FIC Single-target Drugs Annual Revenue Forecast by Region (2025-2030)
- 12.2 Americas Forecast by Country (2025-2030)
- 12.3 APAC Forecast by Region (2025-2030)
- 12.4 Europe Forecast by Country (2025-2030)
- 12.5 Middle East & Africa Forecast by Country (2025-2030)
- 12.6 Global FIC Single-target Drugs Forecast by Type (2025-2030)
- 12.7 Global FIC Single-target Drugs Forecast by Application (2025-2030)
- 13 Key Players Analysis
- 13.1 Pfizer
- 13.1.1 Pfizer Company Information
- 13.1.2 Pfizer FIC Single-target Drugs Product Portfolios and Specifications
- 13.1.3 Pfizer FIC Single-target Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.1.4 Pfizer Main Business Overview
- 13.1.5 Pfizer Latest Developments
- 13.2 Johnson & Johnson
- 13.2.1 Johnson & Johnson Company Information
- 13.2.2 Johnson & Johnson FIC Single-target Drugs Product Portfolios and Specifications
- 13.2.3 Johnson & Johnson FIC Single-target Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.2.4 Johnson & Johnson Main Business Overview
- 13.2.5 Johnson & Johnson Latest Developments
- 13.3 Merck
- 13.3.1 Merck Company Information
- 13.3.2 Merck FIC Single-target Drugs Product Portfolios and Specifications
- 13.3.3 Merck FIC Single-target Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.3.4 Merck Main Business Overview
- 13.3.5 Merck Latest Developments
- 13.4 Roche
- 13.4.1 Roche Company Information
- 13.4.2 Roche FIC Single-target Drugs Product Portfolios and Specifications
- 13.4.3 Roche FIC Single-target Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.4.4 Roche Main Business Overview
- 13.4.5 Roche Latest Developments
- 13.5 Novartis
- 13.5.1 Novartis Company Information
- 13.5.2 Novartis FIC Single-target Drugs Product Portfolios and Specifications
- 13.5.3 Novartis FIC Single-target Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.5.4 Novartis Main Business Overview
- 13.5.5 Novartis Latest Developments
- 13.6 BMS
- 13.6.1 BMS Company Information
- 13.6.2 BMS FIC Single-target Drugs Product Portfolios and Specifications
- 13.6.3 BMS FIC Single-target Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.6.4 BMS Main Business Overview
- 13.6.5 BMS Latest Developments
- 13.7 ImmunoGen
- 13.7.1 ImmunoGen Company Information
- 13.7.2 ImmunoGen FIC Single-target Drugs Product Portfolios and Specifications
- 13.7.3 ImmunoGen FIC Single-target Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.7.4 ImmunoGen Main Business Overview
- 13.7.5 ImmunoGen Latest Developments
- 13.8 Sanofi
- 13.8.1 Sanofi Company Information
- 13.8.2 Sanofi FIC Single-target Drugs Product Portfolios and Specifications
- 13.8.3 Sanofi FIC Single-target Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.8.4 Sanofi Main Business Overview
- 13.8.5 Sanofi Latest Developments
- 13.9 Immunocore
- 13.9.1 Immunocore Company Information
- 13.9.2 Immunocore FIC Single-target Drugs Product Portfolios and Specifications
- 13.9.3 Immunocore FIC Single-target Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.9.4 Immunocore Main Business Overview
- 13.9.5 Immunocore Latest Developments
- 13.10 Genentech
- 13.10.1 Genentech Company Information
- 13.10.2 Genentech FIC Single-target Drugs Product Portfolios and Specifications
- 13.10.3 Genentech FIC Single-target Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.10.4 Genentech Main Business Overview
- 13.10.5 Genentech Latest Developments
- 13.11 Eli Lilly
- 13.11.1 Eli Lilly Company Information
- 13.11.2 Eli Lilly FIC Single-target Drugs Product Portfolios and Specifications
- 13.11.3 Eli Lilly FIC Single-target Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.11.4 Eli Lilly Main Business Overview
- 13.11.5 Eli Lilly Latest Developments
- 13.12 Agios
- 13.12.1 Agios Company Information
- 13.12.2 Agios FIC Single-target Drugs Product Portfolios and Specifications
- 13.12.3 Agios FIC Single-target Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.12.4 Agios Main Business Overview
- 13.12.5 Agios Latest Developments
- 13.13 Boehringer Ingelheim
- 13.13.1 Boehringer Ingelheim Company Information
- 13.13.2 Boehringer Ingelheim FIC Single-target Drugs Product Portfolios and Specifications
- 13.13.3 Boehringer Ingelheim FIC Single-target Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.13.4 Boehringer Ingelheim Main Business Overview
- 13.13.5 Boehringer Ingelheim Latest Developments
- 13.14 Gilead
- 13.14.1 Gilead Company Information
- 13.14.2 Gilead FIC Single-target Drugs Product Portfolios and Specifications
- 13.14.3 Gilead FIC Single-target Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.14.4 Gilead Main Business Overview
- 13.14.5 Gilead Latest Developments
- 13.15 Mallinckrodt
- 13.15.1 Mallinckrodt Company Information
- 13.15.2 Mallinckrodt FIC Single-target Drugs Product Portfolios and Specifications
- 13.15.3 Mallinckrodt FIC Single-target Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.15.4 Mallinckrodt Main Business Overview
- 13.15.5 Mallinckrodt Latest Developments
- 13.16 Phathom
- 13.16.1 Phathom Company Information
- 13.16.2 Phathom FIC Single-target Drugs Product Portfolios and Specifications
- 13.16.3 Phathom FIC Single-target Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.16.4 Phathom Main Business Overview
- 13.16.5 Phathom Latest Developments
- 13.17 Dermavant Sciences
- 13.17.1 Dermavant Sciences Company Information
- 13.17.2 Dermavant Sciences FIC Single-target Drugs Product Portfolios and Specifications
- 13.17.3 Dermavant Sciences FIC Single-target Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.17.4 Dermavant Sciences Main Business Overview
- 13.17.5 Dermavant Sciences Latest Developments
- 13.18 Polarean lmaging
- 13.18.1 Polarean lmaging Company Information
- 13.18.2 Polarean lmaging FIC Single-target Drugs Product Portfolios and Specifications
- 13.18.3 Polarean lmaging FIC Single-target Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.18.4 Polarean lmaging Main Business Overview
- 13.18.5 Polarean lmaging Latest Developments
- 13.19 Marinus
- 13.19.1 Marinus Company Information
- 13.19.2 Marinus FIC Single-target Drugs Product Portfolios and Specifications
- 13.19.3 Marinus FIC Single-target Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.19.4 Marinus Main Business Overview
- 13.19.5 Marinus Latest Developments
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.